235 related articles for article (PubMed ID: 18323546)
1. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Dang C; Fornier M; Sugarman S; Troso-Sandoval T; Lake D; D'Andrea G; Seidman A; Sklarin N; Dickler M; Currie V; Gilewski T; Moynahan ME; Drullinsky P; Robson M; Wasserheit-Leiblich C; Mills N; Steingart R; Panageas K; Norton L; Hudis C
J Clin Oncol; 2008 Mar; 26(8):1216-22. PubMed ID: 18323546
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
3. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
[TBL] [Abstract][Full Text] [Related]
4. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Dang C; Lin N; Moy B; Come S; Sugarman S; Morris P; Abbruzzi A; Chen C; Steingart R; Patil S; Norton L; Winer E; Hudis C
J Clin Oncol; 2010 Jun; 28(18):2982-8. PubMed ID: 20479410
[TBL] [Abstract][Full Text] [Related]
5. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
Morris PG; Iyengar NM; Patil S; Chen C; Abbruzzi A; Lehman R; Steingart R; Oeffinger KC; Lin N; Moy B; Come SE; Winer EP; Norton L; Hudis CA; Dang CT
Cancer; 2013 Nov; 119(22):3943-51. PubMed ID: 24037735
[TBL] [Abstract][Full Text] [Related]
6. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS
J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
9. Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.
Sawaki M; Mukai H; Tokudome N; Nakayama T; Taira N; Mizuno T; Yamamoto Y; Horio A; Watanabe T; Uemura Y; Ohashi Y
Breast Cancer; 2012 Jul; 19(3):253-8. PubMed ID: 21526424
[TBL] [Abstract][Full Text] [Related]
10. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Perez EA; Suman VJ; Davidson NE; Sledge GW; Kaufman PA; Hudis CA; Martino S; Gralow JR; Dakhil SR; Ingle JN; Winer EP; Gelmon KA; Gersh BJ; Jaffe AS; Rodeheffer RJ
J Clin Oncol; 2008 Mar; 26(8):1231-8. PubMed ID: 18250349
[TBL] [Abstract][Full Text] [Related]
11. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.
Abu-Khalaf MM; Juneja V; Chung GG; DiGiovanna MP; Sipples R; McGurk M; Zelterman D; Haffty B; Reiss M; Wackers FJ; Lee FA; Burtness BA
Breast Cancer Res Treat; 2007 Sep; 104(3):341-9. PubMed ID: 17051423
[TBL] [Abstract][Full Text] [Related]
12. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
Bianchi G; Albanell J; Eiermann W; Vitali G; Borquez D; Viganò L; Molina R; Raab G; Locatelli A; Vanhauwere B; Gianni L; Baselga J
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5944-51. PubMed ID: 14676119
[TBL] [Abstract][Full Text] [Related]
13. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
14. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Cortes J; Di Cosimo S; Climent MA; Cortés-Funes H; Lluch A; Gascón P; Mayordomo JI; Gil M; Benavides M; Cirera L; Ojeda B; Rodríguez CA; Trigo JM; Vazquez J; Regueiro P; Dorado JF; Baselga J;
Clin Cancer Res; 2009 Jan; 15(1):307-14. PubMed ID: 19118059
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
16. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
[TBL] [Abstract][Full Text] [Related]
17. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L
Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895
[TBL] [Abstract][Full Text] [Related]
18. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Morris PG; Chen C; Steingart R; Fleisher M; Lin N; Moy B; Come S; Sugarman S; Abbruzzi A; Lehman R; Patil S; Dickler M; McArthur HL; Winer E; Norton L; Hudis CA; Dang CT
Clin Cancer Res; 2011 May; 17(10):3490-9. PubMed ID: 21372222
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
Amadori D; Milandri C; Comella G; Saracchini S; Salvagni S; Barone C; Bordonaro R; Gebbia V; Barbato A; Serra P; Gattuso D; Nanni O; Baconnet B; Gasparini G
Eur J Cancer; 2011 Sep; 47(14):2091-8. PubMed ID: 21665463
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
